Vaxart Inc Stock Current Valuation
| VXRT Stock | USD 0.60 0.01 1.64% |
Valuation analysis of Vaxart Inc helps investors to measure Vaxart's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 127.8 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (1.05) in 2024. Fundamental drivers impacting Vaxart's valuation include:
Price Book 2.0201 | Enterprise Value 97.8 M | Enterprise Value Ebitda (0.17) | Price Sales 9.7881 | Forward PE 42.735 |
Fairly Valued
Today
Please note that Vaxart's price fluctuation is abnormally volatile at this time. Calculation of the real value of Vaxart Inc is based on 3 months time horizon. Increasing Vaxart's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vaxart's intrinsic value may or may not be the same as its current market price of 0.60, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.6 | Real 0.58 | Target 4.5 | Hype 0.6 | Naive 0.59 |
The intrinsic value of Vaxart's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vaxart's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vaxart Inc helps investors to forecast how Vaxart stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaxart more accurately as focusing exclusively on Vaxart's fundamentals will not take into account other important factors: Vaxart Inc Company Current Valuation Analysis
Vaxart's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Vaxart Current Valuation | 97.75 M |
Most of Vaxart's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaxart Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vaxart Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Vaxart is extremely important. It helps to project a fair market value of Vaxart Stock properly, considering its historical fundamentals such as Current Valuation. Since Vaxart's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxart's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxart's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Vaxart Inc has a Current Valuation of 97.75 M. This is 99.32% lower than that of the Biotechnology sector and 97.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.41% higher than that of the company.
Vaxart Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxart's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxart could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics of similar companies.Vaxart is currently under evaluation in current valuation category among its peers.
Vaxart Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vaxart from analyzing Vaxart's financial statements. These drivers represent accounts that assess Vaxart's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vaxart's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.5M | 504.2M | 761.5M | 122.6M | 83.0M | 139.5M | |
| Enterprise Value | (3.7M) | 384.5M | 630.8M | 100.3M | 74.7M | 127.8M |
Vaxart Fundamentals
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (2.54) % | ||||
| Current Valuation | 97.75 M | ||||
| Shares Outstanding | 227.48 M | ||||
| Shares Owned By Insiders | 0.87 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 11.27 M | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 9.79 X | ||||
| Revenue | 7.38 M | ||||
| Gross Profit | (80.95 M) | ||||
| EBITDA | (74.72 M) | ||||
| Net Income | (82.47 M) | ||||
| Cash And Equivalents | 129.55 M | ||||
| Cash Per Share | 1.02 X | ||||
| Total Debt | 26.51 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 8.65 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (70.45 M) | ||||
| Short Ratio | 11.71 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Target Price | 4.83 | ||||
| Number Of Employees | 109 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 136.33 M | ||||
| Total Asset | 91.83 M | ||||
| Retained Earnings | (409.57 M) | ||||
| Working Capital | 31.81 M | ||||
| Net Asset | 91.83 M |
About Vaxart Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxart Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxart using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxart Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.